This article is more than 5 years old. Information may no longer be current.
VIDEO: Rubin Discusses New Biosimilar Data, Inflectra Announcement
Click Here to Manage Email Alerts
LAS VEGAS — In this exclusive video from ACG 2016, David T. Rubin, MD, FACG, professor of medicine at University of Chicago Medicine, discusses Pfizer’s announcement that Inflectra, its biosimilar to Remicade (infliximab, Janssen), will soon be available in the U.S.
“Just in the last 24 hours [it was announced that] the biosimilar to infliximab called Inflectra ... will be available in the United States in November,” he said. “Based on the existing data that have been presented in Europe and Asia, ... it’s expected that there will be payers making switches to these biosimilar agents, or requiring that the biosimilar be used first when a biologic agent is recommended. The data so far have suggested that the agent is safe in that setting.”
Rubin also discusses the results of the NOR-SWITCH presented today at UEG Week.
“Just today [researchers] presented the results of the first and largest prospective, double-blind randomized study of patients in multiple indications undergoing switches from Remicade to the biosimilar or continuing Remicade,” he said. “The study results showed that the patients who continued Remicade compared to those who were switched to the biosimilar agent for infliximab did not have any difference in worsening disease at 1 year, which was the primary outcome.”
Reference:
Rubin DT. Biosimilars are Here! What Every Gastroenterologist Needs to Know. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 17-19, 2016; Las Vegas, NV.
Disclosures: Rubin reports serving on the CCFA Board of Directors and the advisory board for Cornerstones Health Inc., reports consulting for AbbVie Pharmaceuticals, Amgen, Emmi, Janssen, Pfizer, Prometheus Laboratories, Takeda Pharmaceuticals and UCB Pharma, reports receiving research grants from AbbVie, Given Imaging, Janssen, Pfizer, Prometheus Laboratories and UCB, and receives royalties from Slack Publications.